Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Christian P. Selinger. (2014) How costly is non-adherence to infliximab in patients with Crohn’s disease?. Journal of Medical Economics 17:12, pages 881-882.
Read now
Read now
Brian G. Feagan, Chris M. Kozma, Terra L. Slaton, William H. Olson & George J. Wan. (2014) Healthcare costs for Crohn’s disease patients treated with infliximab: a propensity weighted comparison of the effects of treatment adherence. Journal of Medical Economics 17:12, pages 872-880.
Read now
Read now
George J. Wan, Chris M. Kozma, Terra L. Slaton, William H. Olson & Brian G. Feagan. (2014) Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapy. Journal of Medical Economics 17:6, pages 384-393.
Read now
Read now
Doreen Matsui. (2013) Medication adherence issues in patients: focus on cost. Clinical Audit 5, pages 33-42.
Read now
Read now
Articles from other publishers (12)
Qian Cai, Zhijie Ding, Alex Z. Fu & Aarti A. Patel. (2022) Racial or ethnic differences on treatment adherence and persistence among patients with inflammatory bowel diseases initiated with biologic therapies. BMC Gastroenterology 22:1.
Crossref
Crossref
Dominic Pilon, Zhijie Ding, Erik Muser, Ameur M Manceur, Maude Vermette-Laforme, Marie-Hélène Lafeuille & Patrick Lefebvre. (2022) Indicators of Suboptimal Treatment and Associated Healthcare Costs Among Patients With Crohn’s Disease Initiated on Biologic or Conventional Agents. Crohn's & Colitis 360 4:3.
Crossref
Crossref
Farida Islahudin, Fei Yee Lee, Tengku Nur Izzati Tengku Abd Kadir, Muhammad Zulhilmi Abdullah & Mohd Makmor-Bakry. (2021) Continuous medication monitoring: A clinical model to predict adherence to medications among chronic kidney disease patients. Research in Social and Administrative Pharmacy 17:10, pages 1831-1840.
Crossref
Crossref
Joerg Mahlich, Melanie May, Chiara Feig, Vincent Straub & Renate Schmelz. (2021) Persistence With Biologic Therapy and Associated Costs of Patients With Inflammatory Bowel Disease: A German Retrospective Claims Data Analysis. Crohn's & Colitis 360 3:2.
Crossref
Crossref
Jean-Frédéric Colombel, Geert D’haens, Wan-Ju Lee, Joel Petersson & Remo Panaccione. (2020) Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. Journal of Crohn's and Colitis 14:2, pages 254-266.
Crossref
Crossref
Shahnaz Khan, Ewa Rupniewska, Mackenzie Neighbors, David Singer, Joseph Chiarappa & Camilo Obando. (2019) Real‐world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: A systematic review. Journal of Clinical Pharmacy and Therapeutics.
Crossref
Crossref
Jason ShafrinMahlet Gizaw TebekaKwanza PriceChad PatelKaleb Michaud. (2018) The Economic Burden of ACPA-Positive Status Among Patients with Rheumatoid Arthritis. Journal of Managed Care & Specialty Pharmacy 24:1, pages 4-11.
Crossref
Crossref
T Engel, B Ungar, G Ben‐Haim, N Levhar, R Eliakim & S Ben‐Horin. (2017) Re‐phrasing the question: A simple tool for evaluation of adherence to therapy in patients with inflammatory bowel disease. United European Gastroenterology Journal 5:6, pages 880-886.
Crossref
Crossref
David A. Johnson, David Lieberman, John M. Inadomi, Uri Ladabaum, Richard C. Becker, Seth A. Gross, Kristin L. Hood, Susan Kushins, Mark Pochapin & Douglas J. Robertson. (2017) Increased Post-procedural Non-gastrointestinal Adverse Events After Outpatient Colonoscopy in High-risk Patients. Clinical Gastroenterology and Hepatology 15:6, pages 883-891.e9.
Crossref
Crossref
Sara Campos, Francisco Portela, Paula Sousa & Carlos Sofia. (2016) Inflammatory bowel disease. European Journal of Gastroenterology & Hepatology 28:11, pages 1313-1319.
Crossref
Crossref
Eleni Vangeli, Savita Bakhshi, Anna Baker, Abigail Fisher, Delaney Bucknor, Ulrich Mrowietz, Andrew J. K. Östör, Laurent Peyrin-Biroulet, Ana P. Lacerda & John Weinman. (2015) A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory Diseases. Advances in Therapy 32:11, pages 983-1028.
Crossref
Crossref
David S. Vitale, Rachel N. Greenley, Diana G. Lerner, Alisha M. Mavis & Steven L. Werlin. (2015) Adherence to Infliximab Treatment in a Pediatric Inflammatory Bowel Disease Cohort. Journal of Pediatric Gastroenterology & Nutrition 61:4, pages 408-410.
Crossref
Crossref